Synergy Outcomes Study - Metabolic “fatty liver”

Written By Patrick Smith

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease(MASLD).

You may be able to take part in this study if you:

  • Are at least 18 years old

  • Have type 2 diabetes or obesity or overweight

  • Have concern about your liver health

The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo.

If you are considering participating in this clinical research study, please complete the form and someone from our team will reach out to you.

Patrick Smith
Next

ONWARDS 11 Study - Type 1 Diabetes (T1D)